FindTrial
Sign In

PS-341

DRUG6 trials

Sponsors

University of Chicago, National Cancer Institute (NCI), University of Arkansas, UNC Lineberger Comprehensive Cancer Center, H. Lee Moffitt Cancer Center and Research Institute

Conditions

B-Cell LymphomaBreast CancerChronic Myeloproliferative DisordersKidney CancerLeukemiaLymphomaMultiple MyelomaMultiple Myeloma and Plasma Cell Neoplasm

Early Phase 1

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
CompletedNCT00437086
Mayo ClinicChronic Myeloproliferative Disorders, Leukemia
Start: 2005-09-30End: 2008-11-30Target: 30Updated: 2014-10-17

Phase 1

Study of Combination PS-341 and Thalidomide in Multiple Myeloma
CompletedNCT00083460
University of ArkansasMultiple Myeloma
Start: 2001-12-31End: 2007-11-30Updated: 2010-08-02
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
CompletedNCT00237627
UNC Lineberger Comprehensive Cancer CenterBreast Cancer, Leukemia, Lymphoma +3
Start: 2001-05-31End: 2010-01-31Updated: 2012-05-18
A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma
TerminatedNCT00361088
H. Lee Moffitt Cancer Center and Research InstituteMultiple Myeloma
Start: 2005-08-31End: 2007-06-30Updated: 2013-11-25

Phase 2

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
CompletedNCT00054665
National Cancer Institute (NCI)B-Cell Lymphoma
Start: 2003-02-28End: 2009-07-31Updated: 2012-09-11
PS-341 in Treating Patients With Metastatic Kidney Cancer
CompletedNCT00025376
University of ChicagoKidney Cancer
Start: 2001-10-31End: 2006-03-31Updated: 2013-09-05